Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell Esterline

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Diabetes, Obesity & Metabolism|February 24, 2021
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory studyJonas Oldgren, Sanna Laurila, Axel Åkerblom, et al.
Diabetes Care|March 3, 2022
Erratum. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care 2021;44:1334-1343Yvo J M Op den Kamp, Marlies de Ligt, Bas Dautzenberg, et al.
Diabetes, Obesity & Metabolism|December 15, 2020
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 studyMikhail Kosiborod, Otavio Berwanger, Gary G Koch, et al.
Metabolism: Clinical and Experimental|January 2, 2023
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trialAnna Veelen, Charlotte Andriessen, Yvo Op den Kamp, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 26, 2025
Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trialJeffrey M Burns, Jill K Morris, Eric D Vidoni, et al.
Diabetes, Obesity & Metabolism|April 15, 2024
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in KenyaTom White, Viknesh Selvarajah, Fredrik Wolfhagen-Sand, et al.
Nature Metabolism|December 8, 2023
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetesVictoria E R Parker, Darren Robertson, Edmundo Erazo-Tapia, et al.
Molecular Metabolism|October 24, 2022
Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolismYvo J M Op den Kamp, Anne Gemmink, Marlies de Ligt, et al.
Cardiovascular Diabetology|July 31, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialMohammad Abdel Jawad, Remo H M Furtado, Russell Esterline, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled TrialHiddo J L Heerspink, Remo H M Furtado, Otavio Berwanger, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|February 24, 2021
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory studyJonas Oldgren, Sanna Laurila, Axel Åkerblom, et al.
Diabetes Care|March 3, 2022
Erratum. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care 2021;44:1334-1343Yvo J M Op den Kamp, Marlies de Ligt, Bas Dautzenberg, et al.
Diabetes, Obesity & Metabolism|December 15, 2020
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 studyMikhail Kosiborod, Otavio Berwanger, Gary G Koch, et al.
Metabolism: Clinical and Experimental|January 2, 2023
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trialAnna Veelen, Charlotte Andriessen, Yvo Op den Kamp, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 26, 2025
Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trialJeffrey M Burns, Jill K Morris, Eric D Vidoni, et al.
Diabetes, Obesity & Metabolism|April 15, 2024
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in KenyaTom White, Viknesh Selvarajah, Fredrik Wolfhagen-Sand, et al.
Nature Metabolism|December 8, 2023
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetesVictoria E R Parker, Darren Robertson, Edmundo Erazo-Tapia, et al.
Molecular Metabolism|October 24, 2022
Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolismYvo J M Op den Kamp, Anne Gemmink, Marlies de Ligt, et al.
Cardiovascular Diabetology|July 31, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialMohammad Abdel Jawad, Remo H M Furtado, Russell Esterline, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled TrialHiddo J L Heerspink, Remo H M Furtado, Otavio Berwanger, et al.
Pageof 3